166 related articles for article (PubMed ID: 36283211)
21. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
[TBL] [Abstract][Full Text] [Related]
22. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
[TBL] [Abstract][Full Text] [Related]
23. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
24. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
Bubendorf L; Dafni U; Schöbel M; Finn SP; Tischler V; Sejda A; Marchetti A; Thunnissen E; Verbeken EK; Warth A; Sansano I; Cheney R; Speel EJM; Nonaka D; Monkhorst K; Hager H; Martorell M; Savic S; Kerr KM; Tan Q; Tsourti Z; Geiger TR; Kammler R; Schulze K; Das-Gupta A; Shames D; Peters S; Stahel RA;
Lung Cancer; 2017 Sep; 111():143-149. PubMed ID: 28838386
[TBL] [Abstract][Full Text] [Related]
26. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
[TBL] [Abstract][Full Text] [Related]
27. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
28. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
[TBL] [Abstract][Full Text] [Related]
29. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
31. Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma.
Ma K; Huang F; Wang Y; Kang Y; Wang Q; Tang J; Sun P; Lou J; Qiao R; Si J; Cao J; Miao L
Cancer Med; 2022 Nov; 11(22):4389-4397. PubMed ID: 35521981
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
33. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
Finn SP; Addeo A; Dafni U; Thunnissen E; Bubendorf L; Madsen LB; Biernat W; Verbeken E; Hernandez-Losa J; Marchetti A; Cheney R; Warth A; Speel EM; Quinn AM; Monkhorst K; Jantus-Lewintre E; Tischler V; Marti N; Dimopoulou G; Molina-Vila MA; Kammler R; Kerr KM; Peters S; Stahel RA;
J Thorac Oncol; 2021 Jun; 16(6):990-1002. PubMed ID: 33647504
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Blackhall FH; Peters S; Bubendorf L; Dafni U; Kerr KM; Hager H; Soltermann A; O'Byrne KJ; Dooms C; Sejda A; Hernández-Losa J; Marchetti A; Savic S; Tan Q; Thunnissen E; Speel EJ; Cheney R; Nonaka D; de Jong J; Martorell M; Letovanec I; Rosell R; Stahel RA
J Clin Oncol; 2014 Sep; 32(25):2780-7. PubMed ID: 25071109
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
38. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
39. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
40. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.
Wang S; Shi H; Liu T; Li M; Zhou S; Qiu X; Wang Z; Hu W; Guo W; Chen X; Guo H; Shi X; Shi J; Zang Y; Cao J; Wu L
Hepatobiliary Surg Nutr; 2021 Apr; 10(2):172-179. PubMed ID: 33898558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
